ClinicalTrials.gov
public full text
Public Domain
Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome
The goal of this study is to begin to test whether or not pioglitazone, an FDA approved medication used to treat high blood sugar, may be safe and effective in treating Major Depressive Disorder (MDD) in patients with comorbid Metabolic Syndrome (METSYN).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The Effectiveness of Sertraline in Patients Who Have Had Inadequate Response to Escitalopram#855521
- Sertraline Compared With Hypericum Perforatum (St.John's Wort) in Treating Depression#829663
- CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL#1033425
- The Effects of EstroSense®/MD vs Placebo in Improving the Estrogen Profile in Females#1007734
- Sertraline as an antidepressant and inflammatory cytokines in depressive disorders : a systematic review and meta-analysis of randomized double-blind placebo-controlled trials#443711
Record · ID 807261
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive